Loading people...
Jay Lichter is a Managing Director at Avalon Ventures in San Diego, California, where he leads early-stage life sciences and biotechnology investments. After completing his postdoctoral research in human genetics at Yale University, he began his career in the pharmaceutical industry with scientific roles at DuPont Merck. Transitioning to venture capital, Lichter has co-founded and directed more than 15 biotechnology companies, frequently serving as the founding chief executive officer until permanent leadership is established. He established COI Pharmaceuticals, a venture-pharma incubator providing operational support to Avalon's portfolio, and previously guided startups like Otonomy through initial public offerings before its eventual liquidation in 2022. His current focus remains on funding and operating early-stage therapeutics ventures, leveraging his extensive domain expertise in drug discovery and genomics to build scalable life science enterprises.
Jay Lichter stands as a prominent figure in the venture capital landscape, particularly within the life sciences sector. As a Managing Director at Avalon Ventures, he plays a pivotal role in shaping the future of biotechnology and drug discovery. Lichter's work at Avalon Ventures is distinguished by his hands-on approach to company creation, often co-founding and incubating startups from their earliest stages. This model, frequently seen through Avalon's COI Pharmaceuticals initiative, involves bringing together top scientific talent and groundbreaking research to build companies designed to address significant unmet medical needs.
Lichter's investment focus areas are deeply rooted in his scientific background. With a Ph.D. in Biochemistry, he possesses a profound understanding of complex biological processes and therapeutic development. His expertise spans a wide range of biotechnology applications, including novel drug discovery platforms, gene therapies, rare disease treatments, and innovative therapeutic modalities. He is particularly adept at identifying promising scientific discoveries and guiding their translation into viable commercial enterprises, emphasizing rigorous scientific validation and strategic business development.
Before his impactful tenure at Avalon Ventures, Jay Lichter accumulated extensive experience across various facets of the biotech industry. His career background includes significant roles in both academic research and industry leadership, providing him with a comprehensive perspective on the challenges and opportunities inherent in developing new medicines. This blend of scientific acumen and entrepreneurial drive has been instrumental in his success at Avalon, where he has been a driving force behind the creation and growth of numerous successful biotech companies.
Among his notable contributions, Lichter was a key figure in the formation and development of Synageva BioPharma, a company focused on rare diseases that was later acquired by Alexion Pharmaceuticals for over $8 billion. He also played a crucial role in Otonomy, a company developing therapeutics for ear disorders. His portfolio reflects a consistent track record of identifying high-potential ventures and providing the strategic guidance necessary for their growth and ultimate success. Through his leadership at Avalon Ventures, Jay Lichter continues to be a catalyst for innovation, fostering the next generation of life science companies that aim to improve human health globally.
Jay Lichter is a Managing Director at Avalon Ventures, a venture capital firm. He is a highly respected investor and company builder in the life sciences and biotechnology sectors, known for his scientific expertise and entrepreneurial approach.
Jay Lichter primarily invests in life science companies, with a strong focus on biotechnology, therapeutics, and drug discovery. He specializes in creating and incubating early-stage companies that translate scientific breakthroughs into new medicines.
Jay Lichter works as a Managing Director at Avalon Ventures, a prominent venture capital firm. He is based out of their operations, actively involved in the creation and funding of new biotech companies.
